Insufficient T cell infiltration into noninflamed tumors, such as hepatocellular carcinoma (HCC), restricts the effectiveness of immune-checkpoint blockade (ICB) for a subset of patients. Epigenetic therapy provides further opportunities to rewire cancer-associated transcriptional programs, but whether and how selective epigenetic inhibition counteracts the immune-excluded phenotype remain incompletely defined. Here, we showed that pharmacological inhibition of histone deacetylase 8 (HDAC8), a histone H3 lysine 27 (H3K27)–specific isozyme overexpressed in a variety of human cancers, thwarts HCC tumorigenicity in a T cell–dependent manner. The tumor-suppressive effect of selective HDAC8 inhibition was abrogated by CD8+ T cell depletion or regulatory T cell adoptive transfer. Chromatin profiling of human HDAC8-expressing HCCs revealed genome-wide H3K27 deacetylation in 1251 silenced enhancer-target gene pairs that are enriched in metabolic and immune regulators. Mechanistically, down-regulation of HDAC8 increased global and enhancer acetylation of H3K27 to reactivate production of T cell–trafficking chemokines by HCC cells, thus relieving T cell exclusion in both immunodeficient and humanized mouse models. In an HCC preclinical model, selective HDAC8 inhibition increased tumor-infiltrating CD8+ T cells and potentiated eradication of established hepatomas by anti–PD-L1 therapy without evidence of toxicity. Mice treated with HDAC8 and PD-L1 coblockade were protected against subsequent tumor rechallenge as a result of the induction of memory T cells and remained tumor-free for greater than 15 months. Collectively, our study demonstrates that selective HDAC8 inhibition elicits effective and durable responses to ICB by co-opting adaptive immunity through enhancer reprogramming.
Turning immunologically “cold” tumors “hot” is required for effective immune checkpoint inhibitor (ICI) treatment in hepatocellular carcinoma (HCC). Here, we identified Fas-associated death domain (FADD) as a key molecule upregulated in HCC with dense tumor-infiltrating CD8+ T cells and better response to ICIs. CRISPR-mediated knockout of Fadd in murine HCC cells led to increased tumor weights in immunocompetent, but not immunodeficient, mice. FADD deficiency also led to decreased intratumoral infiltration of CD8+ T cells and lower production of IFN-γ and TNF-ɑ. Mechanistically, phosphorylated FADD translocated into the nucleus where it interacted with Sam68 to upregulate NF-κB-induced transcription of CCL5, thereby promoting CD8+ T cell recruitment. Treatment with anti-PD-1 triggered FADD phosphorylation in ICI-sensitive tumors, which was not observed in ICI-resistant tumors. FADD activation through genetic or pharmacologic approaches overcame ICI resistance in orthotopic and spontaneous HCC mouse models in vivo. Together, these findings provide insights into combinatory immunotherapy approaches for HCC patients.
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and has limited therapeutic options. Epigenetic dysregulation plays a crucial role in hepatocarcinogenesis; however, its impact on cis-regulatory elements (CREs) and retrotransposons remains underexplored. Here, we investigated the epigenetic changes underlying the aberrant CRE and retrotransposon activity in HCC. We show that focal DNA hypomethylation of these elements is associated with transcriptional reprogramming. Notably, we uncover a dual regulatory mechanism for GPC3, a key diagnostic biomarker and immunotherapeutic target in HCC. This requires the concomitant reactivation of a fetal liver super-enhancer (SE) and DNA hypomethylation of CpG islands. Furthermore, DNA methylation loss drives cryptic activation of retrotransposons, some of which exhibit prognostic potential. Intriguingly, we identify a HERVE-int-derived long non-coding RNA that shows higher expression in patients with more aggressive tumors, poorer disease outcomes, and is correlated with molecular signatures associated with improved response to immunotherapy. Collectively, our findings reveal widespread epigenomic dysregulation of CREs and retrotransposons in HCC, highlighting new potential therapeutic strategies and biomarkers.